UNSPSC 51321714: Fluvastatin sodium

This classification denotes a hmg-coa reductase inhibitor with the molecular formula C24H25FNO4.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PYF7O1FV7F, chemically known as 6-heptenoic acid, 7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1h-indol-2-yl)-3,5-dihydroxy-, monosodium salt, (r*,s*-(e))-(+-)- but more generally known as fluvastatin sodium, which bears US NIH Compound Identifier 5281101.

UNSPSC 51321714 Fluvastatin sodium is a Commodity code representing specific pharmaceutical products purchased by state and local health agencies, emergency medical services, and multistate cooperative purchasing programs. State and local governments buy this statin medication primarily through emergency response procurement, health benefit programs, and cooperative pharmaceutical contracts that aggregate demand across multiple jurisdictions and healthcare facilities. The issuing bodies include municipal fire and rescue departments, state health and human services agencies, and multistate purchasing cooperatives administering consolidated pharmaceutical supply agreements for participating state and local members.

Recent opportunities show activity across Florida, Texas, and Minnesota through mixed procurement vehicles. The City of Tampa Purchasing Department issued an IFB (Bid No. 26-P-00188) on April 24, 2026, for Advanced Life Support Medications for Tampa Fire Rescue with a due date of April 8, 2026 and estimated contract value of $40,000, though this solicitation names specific emergency medications (Labetalol, Epinephrine, Adenosine, Diltiazem) rather than Fluvastatin. The Texas Health and Human Services Commission issued an RFI (HHS0017013) on April 3, 2026, seeking vendor capabilities for direct-to-manufacturer prescription programs without specifying individual drug products or contract values at that exploratory stage. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (S1070000015802) due March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon, with contract effectiveness July 1, 2026, and a two-year initial term. The Tampa solicitation includes a 5 percent bid discount for Small Local Business Enterprise participation. Recent procurement under this code reflects both emergency responder supply needs and broader state health-system pharmaceutical aggregation, though the specific Commodity code showed limited direct solicitation activity tied explicitly to Fluvastatin during the review period.